Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jiangsu noon crop science co., ltd - paraquat present as paraquat dichloride - soluble concentrate - paraquat present as paraquat dichloride pyridine-bipyridyl active 250.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

wallcann pty ltd - 46293 - sitz bath kit, reusable - sitz bath kit with irrigation, flow-controlled solution bag and tubing and clamps for patient hygiene and external hydrotherapy. rigid basin model and collapsible for storage basin model.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jiangsu yunfan chemical co ltd - clethodim; liquid hydrocarbon - emulsifiable concentrate - clethodim cyclohexanediones active 480.0 g/l; liquid hydrocarbon solvent other 422.0 g/l - herbicide

New Zealand - English - Ministry for Primary Industries

max(rudong) chemicals co., ltd. - prohexadione-calcium - prohexadione-calcium 100 g/kg - plant growth regulator

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

glyphosate 41%

Singapore - English - HSA (Health Sciences Authority)

kingston medical supplies (private) limited - general & plastic surgery - jiangsu yuyue yuwell portable phlegm suction unit 7e-c & 7e-g are intended for use by doctors, medical professionals, nurses and trained personnel for the aspiration of phlegm, mucus and other body fluid in low surgical procedure.

Australia - English - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - ct772 - severe acute respiratory syndrome-associated coronavirus ivds - covid-19 coronavirus real-time pcr kit is an in vitro diagnostic (ivd) reagent replying on fluorescent pcr technology and aiming at qualitatively detect sars-cov-2 novel coronavirus from upper and lower respiratory tract samples. upper respiratory tract samples include throat swab, nasal swab, and nasopharyngeal extract. lower respiratory tract samples include sputum, respiratory tract extract, bronchial perfusate, and bronchoalveolar lavage fluid. sampling objectives include suspected cases infected by sars-cov-2, suspected cases due to crowd gathering, other cases need to be diagnosed with sars-cov-2, and other suspected environmental and biomaterials (for traceability analysis, for example). sampling should be carried out by well-trained professionals with biosafety and experimental skills. typically sars-cov-2 rna could be detected from upper and lower respiratory tract samples if a person is infected. a positive result suggests sars-cov-2 infection but bacteria and other virus-induced co-infection could not be excluded. sars-cov-2 test result is not the only confirmed evidence of suspected cases and all positive results have to be reported to the centers for disease control (cdcs) and authorities. negative results can neither straightforwardly exclude sars-cov-2 infection and nor the only decision-making evidence for treatment and patient management. a negative result should be appropriately used by combining clinical observation, medical history, and epidemiological information. the test is only available to qualified laboratories, certificated clinical pcr laboratories and 15189 certified third-party laboratories with real-time pcr thermal cyclers. operators carrying out sars-cov-2 nucleic acid testing should be well trained with laboratory biosafety and pcr experimental skills.

Australia - English - Department of Health (Therapeutic Goods Administration)

supreme orthodontics supply (aust) pty ltd - 17471 - suture, polyglactin - pgla is a sterile, absorbable synthetic, multifilament surgical suture composed of poly(glycolide-co lactide). it is for single use and after implantation the suture is absorbed by human body during degradation process which is usually 15 days after implantation the suture thread. it would be totally absorbed in 56-70 days and is connected to a 3/8 circle reverse cutting needle of varying sizes. the is a pgla absorbable suture that is indicated for use in soft tissue approximation and/or ligation but not for use in cardiovascular tissue and neurological tissue.

United States - English - NLM (National Library of Medicine)

jiangsu hengrui medicine co., ltd. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 2 mg in 1 ml - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium have been reported [see warnings and precautions ( 5.4)] . the use of 10 ml cisatracurium multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings and

United States - English - NLM (National Library of Medicine)

jiangsu hengrui medicine co., ltd. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 2 mg in 1 ml - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium have been reported [see warnings and precautions ( 5.4)] . the use of 10 ml cisatracurium multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings and